155 related articles for article (PubMed ID: 27149429)
1. Targeting autophagy in antitumor agent design: furthering the 'lysosomal love' strategy.
Sahni S; Kovacevic Z; Kalinowski DS; Huang M; Menezes S; Krishan S; Lane DJ; Jansson PJ; Richardson DR
Future Med Chem; 2016 May; 8(7):727-9. PubMed ID: 27149429
[No Abstract] [Full Text] [Related]
2. NDRG1 suppresses basal and hypoxia-induced autophagy at both the initiation and degradation stages and sensitizes pancreatic cancer cells to lysosomal membrane permeabilization.
Sahni S; Gillson J; Park KC; Chiang S; Leck LYW; Jansson PJ; Richardson DR
Biochim Biophys Acta Gen Subj; 2020 Aug; 1864(8):129625. PubMed ID: 32335136
[TBL] [Abstract][Full Text] [Related]
3. NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy.
Wang H; Li W; Xu J; Zhang T; Zuo D; Zhou Z; Lin B; Wang G; Wang Z; Sun W; Sun M; Chang S; Cai Z; Hua Y
Cell Death Dis; 2017 Sep; 8(9):e3048. PubMed ID: 28906492
[TBL] [Abstract][Full Text] [Related]
4. Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
de Siqueira LRP; de Moraes Gomes PAT; de Lima Ferreira LP; de Melo Rêgo MJB; Leite ACL
Eur J Med Chem; 2019 May; 170():237-260. PubMed ID: 30904782
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT).
Gutierrez EM; Seebacher NA; Arzuman L; Kovacevic Z; Lane DJ; Richardson V; Merlot AM; Lok H; Kalinowski DS; Sahni S; Jansson PJ; Richardson DR
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1665-81. PubMed ID: 27102538
[TBL] [Abstract][Full Text] [Related]
6. Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.
Park KC; Geleta B; Leck LYW; Paluncic J; Chiang S; Jansson PJ; Kovacevic Z; Richardson DR
J Biol Chem; 2020 Jan; 295(2):481-503. PubMed ID: 31744884
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.
Serda M; Kalinowski DS; Mrozek-Wilczkiewicz A; Musiol R; Szurko A; Ratuszna A; Pantarat N; Kovacevic Z; Merlot AM; Richardson DR; Polanski J
Bioorg Med Chem Lett; 2012 Sep; 22(17):5527-31. PubMed ID: 22858101
[TBL] [Abstract][Full Text] [Related]
8. The role of NDRG1 in the pathology and potential treatment of human cancers.
Bae DH; Jansson PJ; Huang ML; Kovacevic Z; Kalinowski D; Lee CS; Sahni S; Richardson DR
J Clin Pathol; 2013 Nov; 66(11):911-7. PubMed ID: 23750037
[TBL] [Abstract][Full Text] [Related]
9. Autophagy: shaping the tumor microenvironment and therapeutic response.
Maes H; Rubio N; Garg AD; Agostinis P
Trends Mol Med; 2013 Jul; 19(7):428-46. PubMed ID: 23714574
[TBL] [Abstract][Full Text] [Related]
10. Copper that cancer with lysosomal love!
Kovacevic Z; Sahni S; Richardson DR
Aging (Albany NY); 2016 Feb; 8(2):210-1. PubMed ID: 26928386
[No Abstract] [Full Text] [Related]
11. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer.
Kovacevic Z; Chikhani S; Lovejoy DB; Richardson DR
Mol Pharmacol; 2011 Oct; 80(4):598-609. PubMed ID: 21719465
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antitumor activity of liquiritigenin thiosemicarbazone derivatives.
Hu K; Yang ZH; Pan SS; Xu HJ; Ren J
Eur J Med Chem; 2010 Aug; 45(8):3453-8. PubMed ID: 20494492
[TBL] [Abstract][Full Text] [Related]
13. Novel R-(+)-limonene-based thiosemicarbazones and their antitumor activity against human tumor cell lines.
Vandresen F; Falzirolli H; Almeida Batista SA; da Silva-Giardini AP; de Oliveira DN; Catharino RR; Ruiz AL; de Carvalho JE; Foglio MA; da Silva CC
Eur J Med Chem; 2014 May; 79():110-6. PubMed ID: 24727464
[TBL] [Abstract][Full Text] [Related]
14. Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells.
Zhao X; Fang Y; Yang Y; Qin Y; Wu P; Wang T; Lai H; Meng L; Wang D; Zheng Z; Lu X; Zhang H; Gao Q; Zhou J; Ma D
Autophagy; 2015; 11(10):1849-63. PubMed ID: 25893854
[TBL] [Abstract][Full Text] [Related]
15. Leaving the lysosome behind: novel developments in autophagy inhibition.
Solitro AR; MacKeigan JP
Future Med Chem; 2016 Jan; 8(1):73-86. PubMed ID: 26689099
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and anticancer activity of novel nopinone-based thiosemicarbazone derivatives.
Wang Y; Gu W; Shan Y; Liu F; Xu X; Yang Y; Zhang Q; Zhang Y; Kuang H; Wang Z; Wang S
Bioorg Med Chem Lett; 2017 Jun; 27(11):2360-2363. PubMed ID: 28431878
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel 5,6-disubstituted pyridine-2,3-dione-3-thiosemicarbazone derivatives as potential anticancer agents.
Xie W; Xie S; Zhou Y; Tang X; Liu J; Yang W; Qiu M
Eur J Med Chem; 2014 Jun; 81():22-7. PubMed ID: 24819956
[TBL] [Abstract][Full Text] [Related]
18. Identification of differential anti-neoplastic activity of copper bis(thiosemicarbazones) that is mediated by intracellular reactive oxygen species generation and lysosomal membrane permeabilization.
Stefani C; Al-Eisawi Z; Jansson PJ; Kalinowski DS; Richardson DR
J Inorg Biochem; 2015 Nov; 152():20-37. PubMed ID: 26335599
[TBL] [Abstract][Full Text] [Related]
19. Reactive oxygen species regulation of autophagy in cancer: implications for cancer treatment.
Li L; Ishdorj G; Gibson SB
Free Radic Biol Med; 2012 Oct; 53(7):1399-410. PubMed ID: 22820461
[TBL] [Abstract][Full Text] [Related]
20. Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics.
Park KC; Fouani L; Jansson PJ; Wooi D; Sahni S; Lane DJ; Palanimuthu D; Lok HC; Kovačević Z; Huang ML; Kalinowski DS; Richardson DR
Metallomics; 2016 Sep; 8(9):874-86. PubMed ID: 27334916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
